Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM8001 in patients with advanced solid tumors and a phase IIa study to investigate the efficacy of PM8001 in patients with advanced solid tumors

Next Previous
X
Search
Trial Profile

A phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM8001 in patients with advanced solid tumors and a phase IIa study to investigate the efficacy of PM8001 in patients with advanced solid tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PM 8001 (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Liver cancer; Liver metastases; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Jun 2022 Results (n=108; 16 Dec 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 03 Dec 2021 Results published in the Biotheus Media Release.
    • 03 Dec 2021 According to a Biotheus media release, this study was approved by the Chinese NMPA in March 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top